{
    "meta": {
        "name": "nbl_v1.2",
        "timestamp": "20241202",
        "sheet_id": "1tdXKN6Al4xtEH2eoIdRM6vEMra1A3bdCQHQIv-IZy6k"
    },
    "info": {
        "title": "Neuroblastoma (NBL) Data Dictionary",
        "name": "nbl_v1.2",
        "release_notes": "https://github.com/chicagopcdc/d4cg-modeling/tree/main/pcdc/nbl/nbl_v1.2",
        "parent_data_model": "pcdc_v1.8",
        "license": "Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/)",
        "wiki": "https://docs.pedscommons.org/",
        "consortium_info": "https://commons.cri.uchicago.edu/pcdc/",
        "description": "The NBL data dictionary is a consensus data schema built by an international group of pediatric neuroblastoma experts and maintained by Data for the Common Good (D4CG) at the University of Chicago in collaboration with the International Neuroblastoma Risk Group (INRG). It is based on the collective requirements of its contributors.",
        "total": 88
    },
    "domains": {
        "": {
            "subject_characteristics": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "AGE_AT_ENROLLMENT": {
                    "type": "Number",
                    "tier": "",
                    "description": "The age (in days) when the subject enrolled in the study.",
                    "codes": [
                        "ncit:C168843"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "YEAR_AT_ENROLLMENT": {
                    "type": "Number",
                    "tier": "",
                    "description": "The year at which a subject enrolled in a study.",
                    "codes": [
                        "ncit:C177353"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "STUDY_ID": {
                    "type": "Code",
                    "tier": "",
                    "description": "A sequence of characters used to identify, name, or characterize the study.",
                    "codes": [],
                    "implementation_notes": [
                        "ConsortiumNote: Some patients will have frontline data already in PCDC, we want to link rather than duplicate data for these patients."
                    ],
                    "mappings": [],
                    "permissible_values": {
                        "BEACON": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TREATMENT_ARM": {
                    "type": "Code",
                    "tier": "",
                    "description": "A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.",
                    "codes": [
                        "C15538"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Active Comparator: Temozolomide": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "D4CGNote: STUDY_ID = \"BEACON\""
                            ],
                            "mappings": []
                        },
                        "Experimental: Bevacizumab + Temozolomide": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "D4CGNote: STUDY_ID = \"BEACON\""
                            ],
                            "mappings": []
                        },
                        "Experimental: Irinotecan + Temozolomide": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "D4CGNote: STUDY_ID = \"BEACON\""
                            ],
                            "mappings": []
                        },
                        "Experimental: Bevacizumab + Irinotecan + Temozolomide": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "D4CGNote: STUDY_ID = \"BEACON\""
                            ],
                            "mappings": []
                        },
                        "Experimental: Temozolomide + Topotecan": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "D4CGNote: STUDY_ID = \"BEACON\""
                            ],
                            "mappings": []
                        },
                        "Experimental: Bevacizumab + Temozolomide + Topotecan": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "D4CGNote: STUDY_ID = \"BEACON\""
                            ],
                            "mappings": []
                        },
                        "Experimental: Dinutuximab beta + Temozolomide": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "D4CGNote: STUDY_ID = \"BEACON\""
                            ],
                            "mappings": []
                        },
                        "Experimental: Dinutuximab beta + Temozolomide + Topotecan": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "D4CGNote: STUDY_ID = \"BEACON\""
                            ],
                            "mappings": []
                        },
                        "Other: Dinutuximab beta + Topotecan + Cyclophosphamide": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "D4CGNote: STUDY_ID = \"BEACON\""
                            ],
                            "mappings": []
                        }
                    }
                },
                "EFS_CENSOR_STATUS": {
                    "type": "Code",
                    "tier": "",
                    "description": "The status of individuals in a study when their outcome (event occurrence or time to event) is censored or not censored at the time of analysis or data collection. Censoring occurs when an individual has not experienced the event of interest by the end of the study period or at the time of data analysis, often because they were lost to follow-up, withdrew from the study, or the study ended before the event could occur. In event-free survival analysis, these censored individuals are included in the analysis up to the point of censoring and are essential for estimating survival probabilities and analyzing the time to events.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Subject is censored (i.e. has had no events(s))": {
                            "description": "The status of a participant or subject in a study whose event or outcome of interest has not yet occurred or has not been observed within the study's follow-up period. Censoring occurs when the event of interest has not happened to a participant by the end of the study or when they are lost to follow-up before the event occurs.",
                            "codes": [
                                "C118962"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Subject has had one or more events": {
                            "description": "The patient has experienced the event of interest within the study period and has reached the endpoint being evaluated, such as disease progression, relapse, recurrence, or death, and their time to event can be accurately recorded and analyzed.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "AGE_AT_CENSOR_STATUS": {
                    "type": "Number",
                    "tier": "",
                    "description": "The age (in days) of the subject at the time of the event censor status.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": []
                }
            },
            "disease_phase_timing": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Relapse/Progression": {
                            "description": "Either the return of the disease or the progression of the disease.",
                            "codes": [
                                "C174991"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Refractory": {
                            "description": "Not responding to treatment.",
                            "codes": [
                                "C38014"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "AGE_AT_DISEASE_PHASE": {
                    "type": "Number",
                    "tier": "",
                    "description": "Age of subject (in days) at the end of the treatment course.",
                    "codes": [
                        "C168851"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "YEAR_AT_DISEASE_PHASE": {
                    "type": "Number",
                    "tier": "",
                    "description": "Age of subject (in days) at the disease phase.",
                    "codes": [
                        "C168972"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                }
            },
            "course_timing": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "CYCLE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "Cycle Number",
                    "codes": [
                        "C166208"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_CYCLE_START": {
                    "type": "Number",
                    "tier": "",
                    "description": "Age in Days at Cycle Start",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_CYCLE_END": {
                    "type": "Number",
                    "tier": "",
                    "description": "Age in Days at Cycle End",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                }
            },
            "demographics": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "SEX": {
                    "type": "Code",
                    "tier": "",
                    "description": "The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female.",
                    "codes": [
                        "ncit:C28421"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Male": {
                            "description": "A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.",
                            "codes": [
                                "C20197"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Female": {
                            "description": "A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.",
                            "codes": [
                                "C16576"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Not known, observed, recorded; or reported as unknown by the data contributor.",
                            "codes": [
                                "C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "survival_characteristics": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_LKSS": {
                    "type": "Number",
                    "tier": "",
                    "description": "The age (in days) when the last known survival status of the subject was captured.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": []
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Relapse/Progression": {
                            "description": "Either the return of the disease or the progression of the disease.",
                            "codes": [
                                "C174991"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Refractory": {
                            "description": "Not responding to treatment.",
                            "codes": [
                                "C38014"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "LKSS": {
                    "type": "Code",
                    "tier": "",
                    "description": "The last known survival status of the subject.",
                    "codes": [
                        "C168931"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Alive": {
                            "description": "Showing characteristics of life; displaying signs of life.",
                            "codes": [
                                "C37987"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Dead": {
                            "description": "The cessation of life.",
                            "codes": [
                                "C28554"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "CAUSE_OF_DEATH": {
                    "type": "Code",
                    "tier": "",
                    "description": "The circumstance or condition that results in the death of a living being.",
                    "codes": [
                        "C81239"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Disease Progression": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Secondary Malignancy": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Treatment-Related Mortality": {
                            "description": "A death that is considered to be causally linked to a treatment.",
                            "codes": [
                                "C166165"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unrelated to Disease or Treatment": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                }
            },
            "tumor_assessment": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Relapse/Progression": {
                            "description": "Either the return of the disease or the progression of the disease.",
                            "codes": [
                                "C174991"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Refractory": {
                            "description": "Not responding to treatment.",
                            "codes": [
                                "C38014"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "TUMOR_CLASSIFICATION": {
                    "type": "Code",
                    "tier": "",
                    "description": "The classification of a tumor based primarily on histopathological characteristics.",
                    "codes": [
                        "C174459"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Primary": {
                            "description": "A tumor at the original site of origin.",
                            "codes": [
                                "C8509"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Metastatic": {
                            "description": "A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.",
                            "codes": [
                                "C3261"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TUMOR_STATE": {
                    "type": "Code",
                    "tier": "",
                    "description": "A condition or state of a tumor at a particular time and a particular tumor site.",
                    "codes": [
                        "C96643"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Present": {
                            "description": "Being or existing in a specified place or at the specified time.",
                            "codes": [
                                "C25626"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Absent": {
                            "description": "Not existing in a specified place at a specified time.",
                            "codes": [
                                "C48190"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Not known, observed, recorded; or reported as unknown by the data contributor.",
                            "codes": [
                                "C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TUMOR_SITE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The anatomic site of the tumor.",
                    "codes": [
                        "C157120"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Central Nervous System": {
                            "description": "The part of the nervous system that consists of the brain, spinal cord, and meninges.",
                            "codes": [
                                "C12438"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Distant Lymph Nodes": {
                            "description": "A lymph node located distant to the anatomic site of interest.",
                            "codes": [
                                "C106042"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Liver": {
                            "description": "A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.",
                            "codes": [
                                "C12392"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Lung": {
                            "description": "One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.",
                            "codes": [
                                "C12468"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Adrenal Gland": {
                            "description": "A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex).",
                            "codes": [
                                "C12666"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Abdomen": {
                            "description": "The cavity located between the lungs and pelvis. It contains the lower esophagus, stomach, pancreas, intestines, liver, gallbladder and spleen.",
                            "codes": [
                                "C12664"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Neck": {
                            "description": "The region that connects the head to the rest of the body.",
                            "codes": [
                                "C13063"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Thorax": {
                            "description": "The division of the body lying between the neck and the abdomen.",
                            "codes": [
                                "C12799"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Pelvis": {
                            "description": "The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.",
                            "codes": [
                                "C12767"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Bone Marrow": {
                            "description": "The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.",
                            "codes": [
                                "C12431"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Bone": {
                            "description": "The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.",
                            "codes": [
                                "C12366"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Skin": {
                            "description": "An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.",
                            "codes": [
                                "C12470"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "TUMOR_SITE_OTHER": {
                    "type": "String",
                    "tier": "",
                    "description": "Specify the \"Other\" Tumor Site.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": []
                }
            },
            "staging": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "STAGE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.",
                    "codes": [
                        "C16899"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "INSS, Stage 1": {
                            "description": "A relatively early stage of cancer that is usually small and contained within the organ it started in, and hasn't spread to other parts of the body",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "INSS, Stage 2a": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "INSS, Stage 2b": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "INSS, Stage 3": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "INSS, Stage 4": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "INSS, Stage 4s": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "histology": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "HISTOLOGY": {
                    "type": "Code",
                    "tier": "",
                    "description": "The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Neuroblastoma (Schwannian Stroma-Poor)": {
                            "description": "Neuroblastoma with minimal or absent Schwannian stroma. This tumor is primarily composed of neuroblasts (immature nerve cells) and is characterized by aggressive behavior and a higher likelihood of metastasis due to the lack of supportive stroma.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)": {
                            "description": "A type of neuroblastic tumor that contains a mixture of mature ganglion cells and immature neuroblasts within abundant Schwannian stroma. The rich stroma suggests a less aggressive tumor compared to Schwannian stroma-poor neuroblastomas.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype": {
                            "description": "A benign neuroblastic tumor where Schwannian stroma is the dominant component, and the tumor is composed mainly of mature ganglion cells with minimal or no immature neuroblasts. The maturing subtype indicates the tumor is well-differentiated, resulting in a favorable prognosis.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Ganglioneuroblastoma, Nodular (Composite)": {
                            "description": "A neuroblastic tumor with a composite structure featuring both nodular regions of immature neuroblasts and areas with mature ganglion cells within Schwannian stroma. The nodular (composite) pattern can complicate the prognosis and treatment due to the presence of both aggressive and less aggressive components.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "HISTOLOGY_GRADE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.",
                    "codes": [
                        "C18000"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Undifferentiated or Poorly Differentiated": {
                            "description": "Tumor cells that are undifferentiated or poorly differentiated lack distinct features of the normal tissue from which they originated. They often resemble primitive or immature cells and have an abnormal appearance and behavior. These tumors typically grow faster, are more aggressive, and have a poorer prognosis compared to well-differentiated tumors.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Differentiating": {
                            "description": "Tumors that are differentiating contain cells that are in the process of maturing or developing characteristics more typical of the tissue of origin. While not fully mature, these tumors show some level of differentiation and may exhibit intermediate behavior, often with a more favorable prognosis compared to undifferentiated or poorly differentiated tumors.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Grade 3": {
                            "description": "Grade 3 is a classification used to describe the aggressiveness of a tumor based on how abnormal the tumor cells look under a microscope and how much they differ from the normal tissue. Grade 3 tumors are considered high-grade, meaning they are poorly differentiated, grow rapidly, and have a higher likelihood of spreading. The high grade reflects a more aggressive cancer with a poorer prognosis compared to lower-grade tumors.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Unknown": {
                            "description": "Not known, observed, recorded; or reported as unknown by the data contributor.",
                            "codes": [
                                "C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "MKI": {
                    "type": "Code",
                    "tier": "",
                    "description": "A tumor cell proliferation measurement represented by the number of cells in mitosis plus the number of cells in karyorrhexis per 5000 cells.",
                    "codes": [
                        "C106317"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[nbl_v1.1].[Disease Characteristics].[MKI] skos:exactMatch [nbl_v1.2].[Histology].[MKI]"
                    ],
                    "permissible_values": {
                        "Low (<2% or <100/5,000 cells)": {
                            "description": "A low MKI indicates a slower rate of cell division and less aggressive tumor behavior.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "[nbl_v1.1].[Disease Characteristics].[MKI].[Low (<2% or <100/5,000 cells)] skos:exactMatch [nbl_v1.2].[Histology].[MKI].[Low (<2% or <100/5,000 cells)]"
                            ]
                        },
                        "Intermediate (2-4% or 100 to <200/5,000 cells)": {
                            "description": "An intermediate MKI suggests a moderate rate of cell division, indicating a tumor with intermediate aggressiveness.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "[nbl_v1.1].[Disease Characteristics].[MKI].[Intermediate (2-4% or 100 to <200/5,000 cells)] skos:exactMatch [nbl_v1.2].[Histology].[MKI].[Intermediate (2-4% or 100 to <200/5,000 cells)]"
                            ]
                        },
                        "High (>4% or >200/5,000 cells)": {
                            "description": "A high MKI indicates a rapid rate of cell division and a more aggressive tumor, often associated with a poorer prognosis.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "[nbl_v1.1].[Disease Characteristics].[MKI].[High (>4% or >200/5,000 cells)] skos:exactMatch [nbl_v1.2].[Histology].[MKI].[High (>4% or >200/5,000 cells)]"
                            ]
                        },
                        "Unknown": {
                            "description": "Not known, observed, recorded; or reported as unknown by the data contributor.",
                            "codes": [
                                "C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[nbl_v1.1].[Disease Characteristics].[MKI].[Unknown] skos:exactMatch [nbl_v1.2].[Histology].[MKI].[Unknown]"
                            ]
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "[nbl_v1.1].[Disease Characteristics].[MKI].[Not Reported] skos:exactMatch [nbl_v1.2].[Histology].[MKI].[Not Reported]"
                            ]
                        }
                    }
                },
                "HISTOLOGY_INPC": {
                    "type": "Code",
                    "tier": "",
                    "description": "Revised INPC Prognostic Group (2003)",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Favorable": {
                            "description": "Histology is considered favorable when the tumor cells resemble normal cells of the tissue of origin and exhibit characteristics that are associated with a better prognosis. This includes features such as well-differentiated cells, low mitotic activity, and a lack of aggressive growth patterns. Tumors with favorable histology tend to be less aggressive, respond better to treatment, and have a higher chance of successful treatment outcomes.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unfavorable": {
                            "description": "Histology is considered unfavorable when the tumor cells are poorly differentiated or undifferentiated, exhibiting characteristics that are associated with a worse prognosis. This includes features such as high mitotic activity, aggressive growth patterns, and a lack of resemblance to normal tissue. Tumors with unfavorable histology tend to be more aggressive, harder to treat, and associated with a higher risk of metastasis and poor outcomes.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Not known, observed, recorded; or reported as unknown by the data contributor.",
                            "codes": [
                                "C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "labs": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Refractory": {
                            "description": "Not responding to treatment.",
                            "codes": [
                                "C38014"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Relapse/Progression": {
                            "description": "Either the return of the disease or the progression of the disease.",
                            "codes": [
                                "C174991"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "LAB_TEST": {
                    "type": "Code",
                    "tier": "",
                    "description": "Laboratory Test",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "LDH": {
                            "description": "A quantitative measurement of the amount of lactate dehydrogenase present in a sample.",
                            "codes": [
                                "C64855"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Ferritin": {
                            "description": "The determination of the amount of ferritin present in a sample.",
                            "codes": [
                                "C74737"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "RESULT_NUMERIC": {
                    "type": "Decimal",
                    "tier": "",
                    "description": "The numeric result of the laboratory test.",
                    "codes": [
                        "ncit:C70952"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "[nbl_v1.1].[Labs].[LAB_RESULT_NUMERIC] skos:exactMatch [nbl_v1.2].[Labs].[RESULT_NUMERIC]"
                    ]
                },
                "RESULT_UNIT": {
                    "type": "Code",
                    "tier": "",
                    "description": "The unit of the numeric result of the laboratory test.",
                    "codes": [
                        "ncit:C173274"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "U/L": {
                            "description": "An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance.",
                            "codes": [
                                "ncit:C67456"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "\u00b5g/L": {
                            "description": "A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.",
                            "codes": [
                                "ncit:C67306"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                }
            },
            "molecular_analysis": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Relapse/Progression": {
                            "description": "Either the return of the disease or the progression of the disease.",
                            "codes": [
                                "C174991"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Refractory": {
                            "description": "Not responding to treatment.",
                            "codes": [
                                "C38014"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "MOLECULAR_ABNORMALITY": {
                    "type": "Code",
                    "tier": "",
                    "description": "The type of variation detected by this genetic analysis.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "MYCN Amplification": {
                            "description": "An increase in the number of copies of the MYCN gene, resulting in the overexpression of the MYCN protein. MYCN amplification is commonly associated with aggressive neuroblastoma and can be a predictor of poor prognosis and a target for specific therapies.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                },
                "GENE1": {
                    "type": "String",
                    "tier": "",
                    "description": "The gene symbol that represents either a single gene that has a mutation or the gene that comprises the 5' portion of the coding sequence involved in a fusion gene mutation.",
                    "codes": [
                        "C173595"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "COPY_NUMBER_STATUS": {
                    "type": "Code",
                    "tier": "",
                    "description": "The status of the copy number.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Gain": {
                            "description": "The acquisition of additional copies of a specific DNA segment, which can include entire chromosomes or smaller DNA regions. In the context of cancer, gains often refer to the increase in the number of copies of chromosomal regions or genes, which can lead to overexpression and tumor development.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Loss": {
                            "description": "The decrease in the number of copies of a specific DNA segment, which can include entire chromosomes or smaller chromosomal regions. This can occur through deletions, where a segment of DNA is removed, or through other mechanisms that result in reduced genetic material. Loss of genetic material can lead to the absence of essential genes, loss of gene function, or reduced gene dosage, which can contribute to disease development, including cancer.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Amplification": {
                            "description": "Amplification refers to an increase in the number of copies of a specific DNA segment, which can include genes or chromosomal regions. This genetic alteration results in the overproduction of the gene or genes located within the amplified region. In cancer, gene amplification can lead to the overexpression of oncogenes, which can drive tumor growth and contribute to cancer progression. Amplification is typically identified through genetic testing techniques such as fluorescence in situ hybridization (FISH), quantitative PCR, or array-based methods.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "No gain/loss/amplification": {
                            "description": "A genetic variation where gain, loss, or exchange of DNA results in monoallelic loss of function mutations in a diploid cell. In the context of tumor suppressor genes, where a single copy is sufficient for functionality, loss of function for the second allele is associated with tumorigenesis.",
                            "codes": [
                                "C18016"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "secondary_malignant_neoplasm": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "AGE_AT_SMN": {
                    "type": "Number",
                    "tier": "",
                    "description": "Age in Days at Secondary Malignant Neoplasm",
                    "codes": [
                        "C168860"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Refractory": {
                            "description": "Not responding to treatment.",
                            "codes": [
                                "C38014"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "Relapse/Progression": {
                            "description": "Either the return of the disease or the progression of the disease.",
                            "codes": [
                                "C174991"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": []
                },
                "SMN": {
                    "type": "Code",
                    "tier": "",
                    "description": "Secondary Malignancy",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": []
                        }
                    }
                }
            },
            "stem_cell_transplant": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "SCT_TYPE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The type of stem cell transplant that the subject received.",
                    "codes": [
                        "C168864"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Autologous, Single": {
                            "description": "An autologous stem cell transplant performed once. In this procedure, a patient's own stem cells are collected, stored, and then reinfused after intensive chemotherapy or radiation therapy. The purpose is to restore the bone marrow and blood cell production that the aggressive treatment has destroyed.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Autologous, Tandem": {
                            "description": "A series of two autologous stem cell transplants performed sequentially, usually within a few months of each other. The tandem transplant approach is designed to maximize the therapeutic effect of high-dose chemotherapy or radiation by repeating the stem cell reinfusion process, offering a more aggressive treatment option for certain cancers.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Not Reported": {
                            "description": "Not provided or available.",
                            "codes": [
                                "C43234"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "TREATMENT_ASSIGNED": {
                    "type": "Code",
                    "tier": "",
                    "description": "Was this treatment assigned?",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                }
            },
            "biopsy_and_surgical_procedures": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "PROCEDURE": {
                    "type": "Code",
                    "tier": "",
                    "description": "A categorization of surgical procedures by type or purpose.",
                    "codes": [
                        "C161601"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Surgical Resection": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "TREATMENT_PERFORMED": {
                    "type": "Code",
                    "tier": "",
                    "description": "Was this treatment assigned?",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                }
            },
            "total_dose": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "REGIMEN": {
                    "type": "Code",
                    "tier": "",
                    "description": "Medication Regimen",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "GPOH Induction": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "COJEC": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "N7": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "COJEC+TVD": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Other": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "REGIMEN_OTHER": {
                    "type": "String",
                    "tier": "",
                    "description": "Medication Regimen Other (free-text)",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "ANTINEOPLASTIC_AGENT": {
                    "type": "Code",
                    "tier": "",
                    "description": "Antineoplastic Agent",
                    "codes": [
                        "C274"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Dinutuximab-beta": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "ConsortiumNote: Anti-GD2"
                            ],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Crizotinib": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "ConsortiumNote: Anti-ALK"
                            ],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Lorlatinib": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "ConsortiumNote: Anti-ALK"
                            ],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "MIBG": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [
                                "ConsortiumNote: MIBG Therapy"
                            ],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "TREATMENT_ASSIGNED": {
                    "type": "Code",
                    "tier": "",
                    "description": "Was this treatment assigned?",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                }
            },
            "radiation_therapy": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Initial Diagnosis": {
                            "description": "The first diagnosis of the individual's condition.",
                            "codes": [
                                "C156813"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "TREATMENT_ASSIGNED": {
                    "type": "Code",
                    "tier": "",
                    "description": "Was this treatment assigned?",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Yes": {
                            "description": "The affirmative response to a question.",
                            "codes": [
                                "ncit:C49488"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "No": {
                            "description": "The non-affirmative response to a question.",
                            "codes": [
                                "ncit:C49487"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                }
            },
            "subject_response": {
                "HONEST_BROKER_SUBJECT_ID": {
                    "type": "String",
                    "tier": "",
                    "description": "The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a \"re-identification code\"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",
                    "codes": [
                        "C168949"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "DISEASE_PHASE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see \"Disease Phase Timing and Course Table\" in the documentation for additional guidance).",
                    "codes": [
                        "C168878"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Refractory": {
                            "description": "Not responding to treatment.",
                            "codes": [
                                "C38014"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Relapse/Progression": {
                            "description": "Either the return of the disease or the progression of the disease.",
                            "codes": [
                                "C174991"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "DISEASE_PHASE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "The number of the disease phase.",
                    "codes": [
                        "C173258"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "CYCLE_NUMBER": {
                    "type": "Number",
                    "tier": "",
                    "description": "Cycle Number",
                    "codes": [
                        "C166208"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                },
                "RESPONSE_CATEGORY": {
                    "type": "Code",
                    "tier": "",
                    "description": "The category used to assess the response to therapy.",
                    "codes": [
                        "C173306"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "Overall Response": {
                            "description": "An assessment of the overall response of the disease to the therapy.",
                            "codes": [
                                "C96613"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Primary Site Response": {
                            "description": "The response at a primary site of a disease or condition to treatment.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Bone Marrow Response": {
                            "description": "The response of the bone marrow to the treatment.",
                            "codes": [
                                "C173307"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Metastatic Soft Tissue and Bone Response": {
                            "description": "The evaluation of how metastatic (spreading) cancer affects and responds to treatment in soft tissues and bones. Metastatic cancer cells originate from the primary tumor and spread to other parts of the body, including soft tissues (like muscles, fat, and connective tissues) and bones. The response can be assessed through imaging studies, biopsies, and other diagnostic tests to determine changes in tumor size, density, and metabolic activity in these areas, which helps guide treatment decisions and prognosis.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "RESPONSE": {
                    "type": "Code",
                    "tier": "",
                    "description": "A standard way to measure how well a cancer patient responds to treatment.",
                    "codes": [
                        "C50995"
                    ],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "RECIST, Complete Response": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "RECIST, Partial Response": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "RECIST, Stable Disease": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "RECIST, Progressive Disease": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "INRC Park 2017, Complete Response": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "INRC Park 2017, Partial Response": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "INRC Park 2017, Stable Disease": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "INRC Park 2017, Minor Response": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "INRC Park 2017, Minimal Disease": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "INRC Park 2017, Progressive Disease": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Not Evaluable": {
                            "description": "",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Not Done": {
                            "description": "Indicates a task, process or examination that has either not been initiated or not been completed.",
                            "codes": [
                                "C49484"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Unknown": {
                            "description": "Reported as unknown by the data contributor.",
                            "codes": [
                                "C17998"
                            ],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        },
                        "Not Involved": {
                            "description": "The indicated response category was not involved in the response assessment.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "MIBG_SCORE_TYPE": {
                    "type": "Code",
                    "tier": "",
                    "description": "The type of response score provided in RESPONSE_MEASUREMENT_NUMERIC",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ],
                    "permissible_values": {
                        "MIBG SIOPEN Score": {
                            "description": "The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0\u20136 scale in 12 anatomical regions.",
                            "codes": [],
                            "implementation_notes": [],
                            "mappings": [
                                "New PD"
                            ]
                        }
                    }
                },
                "MIBG_SCORE": {
                    "type": "Number",
                    "tier": "",
                    "description": "The numeric response of the MIBG score.",
                    "codes": [],
                    "implementation_notes": [],
                    "mappings": [
                        "New VD"
                    ]
                }
            }
        }
    }
}